Trial · NCT06175273
Pediatric Oncology Nutrition Intervention Trial
NCT06175273, Phase 2, Phase 3, Completed, Corey Hawes
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Pediatric Oncology Nutrition Intervention Trial. Trials, record NCT06175273. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06175273
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pediatric Oncology Nutrition Intervention Trial
- NCT number
- NCT06175273
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 20 participants, actual
- Lead sponsor
- Corey Hawes
- Conditions
- Pediatric Cancer, Nutrition Related Cancer, Nutrition Aspect of Cancer, Muscle Loss, Malnutrition, Child
- Interventions
- Oral Nutrition Supplement, Tube Feed, Cyproheptadine, Olanzapine, Standard of Care
- First posted
- 2023-12-18
- Last updated
- 2026-10-08
Source ClinicalTrials.gov
Registered outcomes25
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Body Composition | Baseline, at 3 and 6 months after baseline | Change in quadriceps muscle layer thickness is measured by ultrasound and reported as change from baseline in centimeters. |
| Primary | Change in Body Composition Mid-Upper Arm | Baseline, at 3 and 6 months after baseline | Change in body composition will be measured by mid-upper arm circumference and will be measured in centimeters. |
| Secondary | Participants With Intervention Intolerances | Randomization through end of treatment (6 months) | Intervention intolerances were assessed by using the Common Terminology Criteria for Adverse Events (CTCAE) to determine toxicity grade. |
| Secondary | Change in Weight | Baseline, at 3 and 6 months after baseline | Weight will be measured in kilograms (kg). |
| Secondary | Change in Body Mass Index (BMI) | Baseline, at 3 and 6 months after baseline | Body Mass Index (BMI) will be calculated using weight in pounds (lb) and height in inches (in). |
| Secondary | Change in Biomarker IL-6 | Baseline, at 3 and 6 months after baseline | IL-6 concentrations were measured from blood samples collected via central venous lines. |
| Secondary | Change in Biomarker Leptin | Baseline, at 3 and 6 months after baseline | Leptin concentrations were measured from blood samples collected via central venous lines. |
| Secondary | Change in Total Cholesterol | Baseline, at 3 and 6 months after baseline | Total cholesterol concentrations were measured from blood samples collected via central venous lines. |
| Secondary | Change in Cystatin-C | Baseline, at 3 and 6 months after baseline | Cystatin-C concentrations were measured from blood samples collected from blood samples collected via central venous lines. |
| Secondary | Change in Physical Activity | Baseline, at 3 and 6 months after baseline | Physical activity was assessed using the Lanksy Play-Performance Scale, a measure of Pediatric Functional Status based on parent descriptions of the child's activity and response to treatment. Scores ranges from 0-100, with higher scores indicating greater physical activity and functional status. Results are reported as the change from baseline to each follow-up assessment. |
1 to 10 of 25Source ClinicalTrials.gov
See all 25 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| UL1TR001998 | Kentucky Center for Clinical and Translational Science | KERN, PHILIP A; HARTMANN, KATHERINE E | UNIVERSITY OF KENTUCKY | NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES | 2016 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06175273
GET https://conductscience.org/api/trials/v1/NCT06175273/registered?page=2